Codexis
Codexis, Inc. is an industrial biotechnology company that specializes in engineers enzymes for pharmaceutical and chemical production through biocatalysis. Codexis’ technologies enable scale-up and implementation of biocatalytic solutions to optimize process development, from research to manufacturing. There are currently over 50 pharmaceutical firms using Codexis’ technology, products and services in their manufacturing process development. Codexis creates its products by applying its CodeEvolver® directed evolution technology platform, which introduces genetic mutations into microorganisms. Codexis, Inc. began operations as an independent company in 2002, and became a publicly traded company in 2009. They are located in Redwood City, CA USA
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.
Molecular Assemblies is a San Diego-based company developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, and eventually information storage, nanotechnology and more. Inspired by nature, the company’s proprietary DNA synthesis method is designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably. With a highly experienced executive and scientific team and an expansive intellectual property portfolio, Molecular Assemblies has attracted investments from Agilent Technologies, Cavendish Impact Capital Fund, Data Collective Venture Capital, Eleven Two Capital, Genomics Investment Syndicate, Keshif Ventures, Newport Holdings, LP, and Alexandria Venture Investments.
Molecular Assemblies is a San Diego-based company developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, and eventually information storage, nanotechnology and more. Inspired by nature, the company’s proprietary DNA synthesis method is designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably. With a highly experienced executive and scientific team and an expansive intellectual property portfolio, Molecular Assemblies has attracted investments from Agilent Technologies, Cavendish Impact Capital Fund, Data Collective Venture Capital, Eleven Two Capital, Genomics Investment Syndicate, Keshif Ventures, Newport Holdings, LP, and Alexandria Venture Investments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.